FindTrial
Sign In

Effect of COVID-19 infection on sequelae and survival of lung cancer patients and on anti-cancer treatment and long-term prognosis after recovery from infection

Effect of COVID-19 infection on sequelae and survival of lung cancer patients and on anti-cancer treatment and long-term prognosis after recovery from infection - Effect of COVID-19 infection on the prognosis of lung cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098561
Enrollment
Unknown
Registered
2025-03-11
Start date
2023-04-25
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

COVID-19 infected group:none
COVID-19 non-infected group:none

Sponsors

The First Affiliated Hospital, Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Histopathologically confirmed diagnosis of lung malignancy; 2.Completion of at least 1 cycle of anticancer treatment; 3.Availability of at least one imaging evaluation and complete records of medical history data and follow-up; 4.Voluntary participation in this clinical trial.

Exclusion criteria

Exclusion criteria: 1.No clear pathological diagnosis information; 2.Those with combined important organ insufficiency and those with severe mental disorders; 3.Those who refuse to participate in this clinical experiment.

Design outcomes

Primary

MeasureTime frame
Overall survival ;Number of tumor progression;—

Secondary

MeasureTime frame
COVID-19 aftereffects;—

Countries

China

Contacts

Public ContactLu Wang

The First Affiliated Hospital of Zhejiang Chinese Medicine University

lulumm8809@163.com+86 185 1919 8809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026